MEDNAX (NYSE:MD) issued its quarterly earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.83 by $0.04, Bloomberg Earnings reports. The company had revenue of $910.82 million during the quarter, compared to analyst estimates of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.00 EPS. MEDNAX updated its Q1 guidance to $0.84-0.89 EPS.
Shares of MEDNAX (NYSE MD) traded up $1.25 on Thursday, reaching $56.01. 444,963 shares of the company’s stock traded hands, compared to its average volume of 951,888. MEDNAX has a 52 week low of $40.56 and a 52 week high of $72.13. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.37 and a current ratio of 1.43. The firm has a market cap of $5,056.45, a PE ratio of 16.10, a PEG ratio of 1.34 and a beta of 0.31.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the sale, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.
Several equities research analysts recently commented on the stock. Robert W. Baird boosted their price target on shares of MEDNAX from $48.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a report on Tuesday, February 6th. Stephens set a $62.00 price target on shares of MEDNAX and gave the stock a “buy” rating in a report on Thursday, February 8th. Mizuho reissued a “neutral” rating and issued a $53.00 price target (up previously from $49.00) on shares of MEDNAX in a report on Friday, February 9th. Finally, BMO Capital Markets lifted their target price on shares of MEDNAX from $46.00 to $58.00 and gave the stock a “market perform” rating in a research note on Monday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the stock. MEDNAX has an average rating of “Hold” and a consensus price target of $54.92.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.